机构：[1]Zhejiang Provincial Key Laboratory of Medical Genetics, School of Life Science[2]The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang[3]Xuanwu Hospital,Capital Medical University, Beijing, P.R. China.首都医科大学宣武医院
The use of human T lymphocytes genetically modified to express chimeric antigen receptors on their surfaces has emerged as a promising treatment strategy for malignant tumors. We have transfected primary human peripheral T lymphocytes with a recombinant vector carrying DNA fragments encoding anti-erbB2 scFv/Fc/CD28/CD3 zeta chimeric antigen receptor using electroporation. Transfected T cells have been demonstrated to express anti-erB2 scFv/Fc on their surface and CD28/CD3 zeta intracellularly. These modified T cells were able to specifically bind to erbB2 tumor-associated antigen on target tumor cells. After specific binding, modified T cells were activated to produce high levels of cytokines (not only interferon-gamma but also interluekin-2) and mediate lysis of erbB2-positive human tumor cells in an antigen-specific manner. Furthermore, such genetically modified human T cells significantly delayed the growth of subcutaneous erbB2-positive human xenograft tumors after systemic administration. These preclinical studies suggest that human T cells can be modified genetically and redirected to tumors in cancer patients.
基金：
Zhejiang Provincial Natural Science Foundation of China [Y205171]; Joint Research Foundation for Overseas Chinese of Wenzhou Science and Technology Bureau of China [H20080059]; Science and Technology Project for Overseas Chinese
基金编号：Y205171H20080059
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2013]版：
大类|3 区医学
小类|3 区免疫学3 区医学：研究与实验3 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区免疫学4 区医学：研究与实验4 区肿瘤学
JCR分区：
出版当年[2012]版：
Q2IMMUNOLOGYQ2ONCOLOGYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2ONCOLOGYQ3IMMUNOLOGY
第一作者机构：[1]Zhejiang Provincial Key Laboratory of Medical Genetics, School of Life Science
通讯作者：
通讯机构：[*1]Zhejiang Provincial Key Laboratory of Medical Genetics, School of Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
推荐引用方式(GB/T 7714)：
Chaoyan Wang,Wangxiong Hu,Luxi Shen,et al.Adoptive Antitumor Immunotherapy In Vitro and In Vivo Using Genetically Activated erbB2-specific T Cells[J].JOURNAL OF IMMUNOTHERAPY.2014,37(7):351-359.doi:10.1097/CJI.0000000000000048.
APA：
Chaoyan Wang,Wangxiong Hu,Luxi Shen,Ruiyan Dou,Shengke Zhao...&Hongzhi Li.(2014).Adoptive Antitumor Immunotherapy In Vitro and In Vivo Using Genetically Activated erbB2-specific T Cells.JOURNAL OF IMMUNOTHERAPY,37,(7)
MLA：
Chaoyan Wang,et al."Adoptive Antitumor Immunotherapy In Vitro and In Vivo Using Genetically Activated erbB2-specific T Cells".JOURNAL OF IMMUNOTHERAPY 37..7(2014):351-359
